Patagonia Awarded $1.5MM Grant from the FDA
Patagonia is excited to announce that we have been awarded a grant of $1.5MM over three years through FDA's Orphan Products Clinical...
Thank you FIRST!
Our team just returned from Nashville, TN, where FIRST hosted their biennial, national conference. It was a fantastic opportunity to...
FDA Commissioner Gottlieb Outlines Efforts to Advance Biotechnology Innovation
In a recent blog post from the FDA, Commissioner Scott Gottlieb acknowledges their role to help advance progress in biotechnology. Their...
We're headed to Nashville!
Our team is excited to attend the 20th Biennial FIRST National Conference in Nashville, TN next month. This will be our second time...
Recent Budget Approval Increases Funding Across Nearly All US Science Agencies
In March, the President signed the 2018 legislation that increased the budget for nearly all US science agencies, a $1.3 trillion...
Today is Rare Disease Day 2018!
Each year, on the last day of February, Rare Disease Day is held to raise awareness of rare diseases. On and around this day hundreds of...
Patagonia Completes Phase 2a Clinical Study for PAT-001
Patagonia is excited to announce the completion of our Phase 2a clinical study for PAT-001. This proof-of-concept study was conducted at...
Patagonia Completes Enrollment in Phase IIa Study
Patagonia is excited to announce that we have completed enrollment in our Phase IIa study for congenital ichthyosis. Ichthyosis is a...
Developing Drugs for Rare Diseases: Insights for Pharma Execs
John Maslowski recently published a very interesting article in Pharmaceutical Executive detailing various insights and information...
FDA is Advancing the Goals of the Orphan Drug Act
FDA Commissioner Gottlieb writes a post on the FDA's commitment to the Orphan Drug Act in the FDA Voice blog. Please click the following...
